Potent anti-inflammatory agent escin does not affect the healing of tibia fracture and abdominal wound in an animal model
Escin, a potent anti-inflammatory and anti-edematous agent, has been widely used clinically in preventing inflammatory edema after trauma, such as fracture and surgery. The aim of this study was to investigate whether escin has an inhibitory effect on fracture healing, and whether escin has an inhibitory effect on wound healing after surgery. Male New Zealand white rabbits underwent tibial mid-diaphyseal osteotomy, and were administered escin once per day for 10 days. At weeks 2, 4 and 6, bone fracture healing and bone mineral density were measured. The histologic examination of callus, osteocalcin, alkaline phosphatase, calcium and phosphate in the serum were also assayed. In another experiment, the rats underwent midline laparotomy, and received escin once prior to or after the operation. Six days later, the abdominal incision wounds were excised for measuring hydroxyproline levels. The results showed that there were no significant differences in fracture healing between the model and rabbits administered escin, and escin did not affect the hydroxyproline levels in the abdominal incision wounds of the rats. These findings suggest that escin has no inhibitory effect on fracture and wound healing in animal models.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Experimental and therapeutic medicine - 3(2012), 4 vom: 01. Apr., Seite 735-739 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Leiming [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.10.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM220952337 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM220952337 | ||
| 003 | DE-627 | ||
| 005 | 20231224050654.0 | ||
| 007 | tu | ||
| 008 | 231224s2012 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0736.xml |
| 035 | |a (DE-627)NLM220952337 | ||
| 035 | |a (NLM)22969961 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Leiming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potent anti-inflammatory agent escin does not affect the healing of tibia fracture and abdominal wound in an animal model |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Escin, a potent anti-inflammatory and anti-edematous agent, has been widely used clinically in preventing inflammatory edema after trauma, such as fracture and surgery. The aim of this study was to investigate whether escin has an inhibitory effect on fracture healing, and whether escin has an inhibitory effect on wound healing after surgery. Male New Zealand white rabbits underwent tibial mid-diaphyseal osteotomy, and were administered escin once per day for 10 days. At weeks 2, 4 and 6, bone fracture healing and bone mineral density were measured. The histologic examination of callus, osteocalcin, alkaline phosphatase, calcium and phosphate in the serum were also assayed. In another experiment, the rats underwent midline laparotomy, and received escin once prior to or after the operation. Six days later, the abdominal incision wounds were excised for measuring hydroxyproline levels. The results showed that there were no significant differences in fracture healing between the model and rabbits administered escin, and escin did not affect the hydroxyproline levels in the abdominal incision wounds of the rats. These findings suggest that escin has no inhibitory effect on fracture and wound healing in animal models | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Wang, Hongsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Pengfei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Feiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Yating |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Fenghua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental and therapeutic medicine |d 2010 |g 3(2012), 4 vom: 01. Apr., Seite 735-739 |w (DE-627)NLM206343205 |x 1792-1015 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2012 |g number:4 |g day:01 |g month:04 |g pages:735-739 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2012 |e 4 |b 01 |c 04 |h 735-739 | ||